Reframing SpO tolerance as a physiological switch: implications for hypoxic adaptation and exercise regulation.

Reframing SpO tolerance as a physiological switch: implications for hypoxic adaptation and exercise regulation.

Publication date: Jul 16, 2025

Blood oxygen saturation (SpO) is a widely used oxygenation index in clinical and physiological settings. However, recent phenomena, such as asymptomatic hypoxia in COVID-19 and the superior performance of athletes in high-altitude conditions under hypoxia, have highlighted the significant variability in individual tolerance to blood oxygen saturation. Age, health status, disease, and hypoxic adaptation influence it. This brief review introduces the concept of the SpO switch as a dynamic. We also proposed a physiological compensatory response of SpO switch to SpO criticality that triggers compensatory responses, including ventilatory, autonomic, cardiovascular, and metabolic adaptations. Furthermore, individuals can exhibit markedly different responses to hypoxia at the same SpO value. It reflects a “threshold switch mechanism” driven by an individual’s internal physiological settings. This suggests that the SpO value demonstrates the onset of hypoxia symptoms and reacts to the body’s difference in compensatory capacity. This reconceptualisation shifts the focus from static thresholds to dynamic response analysis, offering new perspectives for precision health, mountain medicine, and personalised risk assessment of hypoxia.

Open Access PDF

Concepts Keywords
Cardiovascular hypoxia adaptation
Covid intermittent hypoxia training
Medicine physiological switch
Mountain SpO2 criticality
Reconceptualisation SpO2 switch
threshold response

Semantics

Type Source Name
disease IDO blood
drug DRUGBANK Oxygen
disease MESH hypoxia
disease MESH COVID-19
disease MESH health status
drug DRUGBANK Coenzyme M
pathway REACTOME Reproduction
pathway REACTOME Metabolism
drug DRUGBANK Carbon dioxide
drug DRUGBANK Medical air
disease IDO history
disease IDO susceptibility
disease MESH mountain sickness
disease MESH pulmonary edema
disease MESH cerebral edema
disease MESH dyspnea
disease MESH chronic diseases
disease MESH COPD
disease MESH infection
drug DRUGBANK (S)-Des-Me-Ampa
disease MESH hypercapnia
disease MESH complications
disease MESH obesity
drug DRUGBANK Isoxaflutole
disease MESH heart failure
disease MESH emergencies
disease IDO intervention
disease MESH muscle fatigue
disease MESH dissociation
disease MESH delayed treatment
drug DRUGBANK Caffeine
disease MESH pulmonary hypertension
disease MESH impaired glucose tolerance
disease MESH oxidative stress
disease MESH cardiovascular diseases
disease MESH lung disease
disease MESH etiology
disease MESH critically ill
disease MESH pneumonia

Original Article

(Visited 4 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *